See one of the world's most prestigious awards, the #NobelPeacePrize, up close during #OPCW Open Day! 🏅 OPCW received the #NobelPrize in 2013 for its extensive efforts to eliminate #ChemicalWeapons.
🗓️ 24 September
📍 The Hague
➡️ Register: https://www.eventbrite.com/e/just-peace-open-day-2023-opcw-tickets-680792266997?aff=odcleoeventsincollection&keep_tld=1
📣 Registration is now open for #OPCW Open Day! Join us on 24 September to learn about the OPCW's work, take part in interactive activities, view expert presentations, and more! Details & register ➡️ https://www.eventbrite.com/e/just-peace-open-day-2023-opcw-tickets-680792266997?aff=odcleoeventsincollection&keep_tld=1
2023 is looking to be a breakout year for Lumen; even more non-dilutive funding, and 4 or more drugs in the clinic, all due to an integrated biologics design and manufacturing platform powered by electricity that economically outcompetes everything else by orders of magnitude.
---
RT @LumenBio
Jonathan D. Grinstein speaks with Brian @Finrow (Lumen, CEO) at #JPM23
Read the full article below,
https://www.genengnews.com/industry-news/re…
https://twitter.com/LumenBio/status/1613985615640686593
Controversial method that purported to induce pluripotency via mildly adverse conditions suffers another blow, as RIKEN discontinues replication efforts, accepts resignation of method's lead developer.
“I usually let this stuff go, but this is too over the top In splashy #JPM23 PR, @abscibio claim they can de novo design antibodies from scratch, but they actually design just the CDR3 (of 6 total) of existing Tx antibodies to their orig targets. That's not de novo design”
Interesting slide from @BertrandBio (attending #JPM23 I aussume) concerning biosimilar patent stretch with Entyvia.
How Big Pharma gets 3-5y of add. peak sales for almost nothing in the US, in 1 slide: #SystemFAIL
Ipsen to buy rare disease biotech Albireo Pharma.
https://endpts.com/at-jpm23-another-rare-disease-drugmaker-albireo-gets-bought-by-ipsen
Before most JPMers arose Monday morning, Ipsen announced that it is buying rare disease biotech Albireo Pharma. That’s the second deal disclosed Monday morning, along with AstraZeneca grabbing cardiovascular upstart CinCor Pharma. With the Chiesi-Amryt rare disease deal from Sunday night, that’s three M&A announcements to kick off the annual
OPCW
David J. Whelan
Rob Carlson
Lucas Nivon
Kazuki Yoshida
Pierre A Fournier
International Patent Reviews
Dominic Tyer